Curie Oncology
Curie Oncology is a Singapore-headquartered boutique oncology practice providing complex, multi-disciplinary cancer care through molecular targeted therapies, advanced genomic diagnostics, and locoregional treatments across four private hospital locations in Singapore with affiliated services in Malaysia and the Philippines.
- Company typePrivate
- Founded2018
- HeadquartersSingapore, Singapore
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Curie Oncology does
Curie Oncology Pte Ltd is a Singapore-headquartered boutique medical oncology practice that delivers complex, multi-disciplinary cancer care through molecular targeted treatments, immunotherapy, and precision diagnostics. It operates from four premium private hospital specialist centre locations in Singapore — Mount Elizabeth Novena (HQ, units at #08-21 and #08-29/30), Farrer Park Medical Centre, Mount Elizabeth Medical Centre, and Gleneagles Medical Centre — and extends its reach through affiliated physicians at Penang Adventist Hospital in Malaysia and in Cebu, Philippines. The clinical offering spans a broad portfolio of advanced genomic diagnostics (Signatera, Guardant 360, FoundationOne CDx/Heme, Tempus WES, CARIS Molecular Intelligence, Oncotype DX, MammaPrint, Prolaris, Invitae, OncoStrands, Lucence), locoregional and systemic therapies (TACE, SIRT, SBRT, HIPEC, RFA, Lutetium-PSMA, Lutetium-DOTATATE), haematopoietic cell transplantation, apheresis, and supportive care (cold cap therapy).
The practice is organised around wholly-owned subsidiaries Curie Genetics (hereditary cancer and molecular genetic testing with counselling) and Vickycares (home specialty nursing for oncology and palliative care), and integrates third-party AI and functional precision medicine platforms including Kyan Optim.AI. Revenue is generated primarily from professional services — consultations, chemotherapy infusions, genomic and diagnostic tests, therapeutic procedures, and haematopoietic cell transplantation — billed predominantly through insurance panel relationships (14 named partners including Aetna, AIA, Allianz, Cigna, Great Eastern, HSBC, Prudential, Singlife) and Medisave accreditation. The only publicly disclosed price point is teleconsultation at SGD 500 per approximately 30-minute session for second opinions and assessments. Patient acquisition relies on physician referrals, insurance panel inclusion, an educational content and video library, and direct teleconsultation booking, with no public evidence of external institutional investment.
Curie Oncology firmographics
Firmographics- Name
- Curie Oncology
- Legal name
- Curie Oncology Pte Ltd
- Website
- https://curieoncology.com.sg
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Curie Oncology is a Singapore-headquartered boutique oncology practice providing complex, multi-disciplinary cancer care through molecular targeted therapies, advanced genomic diagnostics, and locoregional treatments across four private hospital locations in Singapore with affiliated services in Malaysia and the Philippines.
- Ownership category
- akta.pro rank
Curie Oncology industry classification
Industry- Product category
- Oncology Services
- NAICS
- Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industry
- Oncology Telemedicine Platforms (HLALAGAH)
Keywords
Where Curie Oncology is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices5 records
Markets served
Curie Oncology business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Consultation and Treatment Services: Revenue generated from medical consultations, chemotherapy infusions, diagnostic tests, and therapeutic procedures provided to cancer patients at their specialist centres.
- Teleconsultation Services: Fee-for-service teleconsultation model at SGD 500 for approximately 30 minutes for second opinions and initial assessments.
- Genomic and Diagnostic Testing: Revenue from advanced genomic testing services including liquid biopsies, tumour profiling, and molecular diagnostics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Teleconsultation - Initial consultation for second opinion or assessment |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Curie Oncology product offering
Product offeringCore offering
Curie Oncology is a boutique oncology practice providing complex cancer care through molecular targeted treatments, immunotherapy, and precision diagnostics. The practice offers advanced genomic testing (including Signatera, Guardant 360, FoundationOne CDx, Tempus, Oncotype DX, MammaPrint, Prolaris, CARIS Molecular Intelligence), targeted therapies (HIPEC, TACE, SIRT, SBRT, Lutetium-DOTATATE, Lutetium-PSMA, RFA), and supportive services including haematopoietic cell transplantation and teleconsultation.
Product overview
Curie Oncology is a boutique oncology practice providing complex cancer care through a multi-disciplinary, personalised approach. The company offers a comprehensive portfolio spanning advanced genomic diagnostic tests (including Signatera, Guardant 360, FoundationOne CDx, Tempus Whole Exome Sequencing, CARIS Molecular Intelligence, Oncotype DX, MammaPrint, Prolaris, OncoStrands, and Invitae genetic testing), targeted therapies (TACE, SIRT, SBRT, Leutetium-DOTATATE, Leutetium-PSMA, HIPEC, RFA), supportive care services (cold cap for hair loss, apheresis), and haematopoietic cell transplantation. The practice also offers teleconsultation for remote patient assessment. Curie Oncology operates across multiple Singapore locations including Mount Elizabeth Novena, Farrer Park, and Gleneagles, with affiliated physicians in Malaysia (Penang) and the Philippines (Cebu).
Differentiator
Problem solved
Functional benefit
Brands
- Curie Genetics: Genetic testing services for cancer patients
- Vickycares
Quantifiable outcome
- Supported more than 100 HIPEC procedures
Companies that use Curie Oncology
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Curie Oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability16 records
Feature6 records
Curie Oncology partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Curie GeneticscoreCurie Genetics is an affiliated company providing genetic testing services including hereditary cancer risk assessment and molecular diagnostics. The partnership enables integrated genetic testing and counselling services for Curie Oncology patients, with Curie Genetics operating as a panel partner for genetic testing services.
- VickycarescoreHome Specialty Nurses partnership providing home-based nursing care services for oncology and palliative patients. Vickycares provides specialized nurses to support Curie Oncology's home care service offerings, enabling patients to receive care in their homes.
- Insurance Panel PartnerscorePartnership with major insurance providers including Aetna, AIA, Allianz, Cigna, Fullerton, Great Eastern, HSBC, IHP, Income, International Assist, iXchange, MHC, Singlife, and Prudential for panel access.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Curie Oncology competitors and assessment
Company assessmentDirect peers
- Icon Cancer Centre: Operates private oncology day hospitals across Singapore and broader Southeast Asia (Malaysia, Vietnam) offering chemotherapy, immunotherapy, and hematology services. Comparable as a multi-country private oncology provider with similar precision-medicine orientation and insurer panel relationships.
- OncoCare Cancer Centre: Singapore-based boutique medical oncology practice offering personalized cancer care, chemotherapy, targeted therapy, and genomic-guided treatment at multiple specialist medical centers. Closely comparable in scale, positioning, and Singapore specialist-center footprint.
- Singapore Oncology Consultants: Singapore-based specialist oncology practice providing medical oncology consultations, chemotherapy administration, and targeted therapies. Direct comparable as a similarly-sized boutique oncology practice serving complex cases at specialist medical centers in Singapore.
- Parkway Cancer Centre: Operates specialist oncology services across Parkway Pantai hospital network in Singapore, offering chemotherapy, immunotherapy, and targeted therapies with multi-disciplinary tumor boards. Directly comparable as a Singapore-based private oncology practice serving complex cancer cases with insurance panel access.
Broad incumbents
- National Cancer Centre Singapore (NCCS): Singapore's flagship public-sector national cancer center providing full-spectrum oncology care including complex cases, clinical trials, and specialty programs. Comparable in serving complex oncology cases in Singapore but operates as a public-sector incumbent at substantially larger scale.
- Mount Elizabeth Hospital (Oncology Services): Major Singapore private hospital where Curie operates two of its specialist centers (Novena and Orchard); offers broader oncology, hematology, and bone marrow transplant services as part of an integrated multi-specialty hospital. Comparable as a Singapore oncology services provider but at broader institutional scale.
Regional players
- Sunway Cancer Centre: Malaysia-based oncology service line within Sunway Medical Centre offering chemotherapy, radiotherapy, targeted therapy, and hematology services. Comparable as a private-sector Southeast Asian oncology provider, though embedded in a larger general hospital group.
- Thomson Hospital Oncology Centre: Malaysia-based private hospital with dedicated oncology services offering chemotherapy, radiotherapy, and targeted therapies in the Klang Valley. Comparable as a Southeast Asian private-sector oncology provider, though operated from a single hospital campus rather than a distributed specialist-center model.
- Beacon Hospital: Malaysia-based private specialty hospital offering oncology, hematology, and stem cell transplantation services. Comparable in offering complex oncology and hematology services (including HCT) within Southeast Asia, though operating from a single integrated hospital site.
Others
- Lucence (now partly owned diagnostics partner): Singapore-headquartered precision oncology company providing liquid biopsy and hereditary cancer testing - currently a technology integration partner of Curie Oncology. Comparable as an adjacent ecosystem player in Southeast Asian precision oncology rather than a direct clinical competitor.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Curie Oncology social profiles
Digital presenceCurie Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curie Oncology leadership team
Management profileNumber of profiles
Profiles1 record
Curie Oncology subsidiaries and ownership
Company hierarchySubsidiaries3 records
Curie Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curie Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curie Oncology
What does Curie Oncology do?
Curie Oncology is a boutique oncology practice providing complex cancer care through molecular targeted treatments, immunotherapy, and precision diagnostics. The practice offers advanced genomic testing (including Signatera, Guardant 360, FoundationOne CDx, Tempus, Oncotype DX, MammaPrint, Prolaris, CARIS Molecular Intelligence), targeted therapies (HIPEC, TACE, SIRT, SBRT, Lutetium-DOTATATE, Lutetium-PSMA, RFA), and supportive services including haematopoietic cell transplantation and teleconsultation.
Is Curie Oncology a public or private company?
Curie Oncology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Curie Oncology founded?
Curie Oncology was founded in 2018. It employs 51 to 100 people.
Where is Curie Oncology based?
Curie Oncology is headquartered in Singapore, Singapore, in the Asia region.
How does Curie Oncology make money?
Three revenue lines are on record. Medical Consultation and Treatment Services are the primary driver. The others are teleconsultation Services and genomic and Diagnostic Testing.
Who are Curie Oncology's main competitors?
Direct peers on record are Icon Cancer Centre, OncoCare Cancer Centre, Singapore Oncology Consultants and Parkway Cancer Centre. Broad incumbents are National Cancer Centre Singapore (NCCS) and Mount Elizabeth Hospital (Oncology Services). Regional players are Sunway Cancer Centre, Thomson Hospital Oncology Centre and Beacon Hospital. Lucence (now partly owned diagnostics partner) is listed as an others.
Does Curie Oncology have an API?
No public API is recorded for Curie Oncology.
What industry is Curie Oncology in?
Curie Oncology's product category is Oncology Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 6215 and its SIC code is 8011.